PL265 is a preclinical, long-acting dual ENKephalinase inhibitor (DENKi), with analgesic potential. PL65 has been developed as a novel therapeutic for control of intractable cancer pain. References: Bonnard E, Poras H, Fournié-Zaluski MC, Roques BP. Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain. Eur J Pharmacol. 2016 Oct 5;788:176-82. doi: 10.1016/j.ejphar.2016.05.041. Epub 2016 Jun 4. PubMed PMID: 27266667.

纯度：≥98%

CAS：1206514-62-6